Met Life Investment Management, LLC Y M Abs Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 22,141 shares of YMAB stock, worth $246,650. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,141
Previous 22,141 -0.0%
Holding current value
$246,650
Previous $267,000 8.61%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$11.6 - $17.25 $23,838 - $35,448
2,055 Added 10.23%
22,141 $267,000
Q1 2024

May 14, 2024
BUY
$6.57 - $18.69 $131,965 - $375,407
20,086 New
20,086 $326,000
Q2 2023

Apr 29, 2024
BUY
$5.68 - $10.34 $114,088 - $207,689
20,086 New
20,086 $136,000
Q1 2023

May 09, 2024
BUY
$2.83 - $5.11 $56,843 - $102,639
20,086 New
20,086 $101 Million
Q1 2023

May 15, 2023
BUY
$2.83 - $5.11 $19,512 - $35,233
6,895 Added 52.27%
20,086 $100,000
Q4 2022

May 10, 2024
SELL
$3.0 - $15.17 $22,476 - $113,653
-7,492 Reduced 36.22%
13,191 $64,000
Q4 2022

Jun 14, 2023
SELL
$3.0 - $15.17 $20,685 - $104,597
-6,895 Reduced 34.33%
13,191 $64,000
Q4 2022

Mar 22, 2023
SELL
$3.0 - $15.17 $22,476 - $113,653
-7,492 Reduced 36.22%
13,191 $64,000
Q4 2022

Feb 15, 2023
SELL
$3.0 - $15.17 $22,476 - $113,653
-7,492 Reduced 36.22%
13,191 $64,000
Q3 2022

Jun 14, 2023
BUY
$13.96 - $19.67 $8,334 - $11,742
597 Added 2.97%
20,683 $298,000
Q2 2022

Jun 20, 2023
BUY
$8.22 - $15.13 $4,907 - $9,032
597 Added 2.97%
20,683 $312,000
Q1 2022

May 10, 2024
BUY
$6.55 - $17.42 $135,473 - $360,297
20,683 New
20,683 $245,000
Q1 2022

Jun 20, 2023
BUY
$6.55 - $17.42 $3,910 - $10,399
597 Added 2.97%
20,683 $245,000
Q1 2022

Mar 22, 2023
BUY
$6.55 - $17.42 $47,605 - $126,608
7,268 Added 54.18%
20,683 $245,000
Q1 2022

May 12, 2022
BUY
$6.55 - $17.42 $47,605 - $126,608
7,268 Added 54.18%
20,683 $246,000
Q4 2021

Jun 21, 2023
SELL
$15.51 - $29.31 $103,467 - $195,527
-6,671 Reduced 33.21%
13,415 $217,000
Q3 2021

Jun 21, 2023
SELL
$27.47 - $37.31 $183,252 - $248,895
-6,671 Reduced 33.21%
13,415 $382,000
Q2 2021

Jun 21, 2023
SELL
$25.45 - $37.64 $169,776 - $251,096
-6,671 Reduced 33.21%
13,415 $453,000
Q1 2021

May 17, 2024
SELL
$29.16 - $51.96 $194,526 - $346,625
-6,671 Reduced 33.21%
13,415 $405,000
Q1 2021

Jun 26, 2023
SELL
$29.16 - $51.96 $194,526 - $346,625
-6,671 Reduced 33.21%
13,415 $406 Million
Q4 2020

Jun 22, 2023
SELL
$37.86 - $54.26 $252,564 - $361,968
-6,671 Reduced 33.21%
13,415 $664,000
Q3 2020

Jun 26, 2023
SELL
$35.13 - $43.62 $234,352 - $290,989
-6,671 Reduced 33.21%
13,415 $515,000
Q2 2020

May 24, 2024
SELL
$23.66 - $49.53 $157,835 - $330,414
-6,671 Reduced 33.21%
13,415 $580 Million
Q2 2020

Jun 26, 2023
SELL
$23.66 - $49.53 $157,835 - $330,414
-6,671 Reduced 33.21%
13,415 $579,000
Q2 2020

Mar 22, 2023
BUY
$23.66 - $49.53 $79,119 - $165,628
3,344 Added 33.2%
13,415 $579,000
Q2 2020

Aug 14, 2020
BUY
$23.66 - $49.53 $79,119 - $165,628
3,344 Added 33.2%
13,415 $580,000
Q1 2020

Jul 12, 2023
SELL
$14.39 - $35.8 $144,115 - $358,537
-10,015 Reduced 49.86%
10,071 $262,000
Q4 2019

Jul 12, 2023
SELL
$23.81 - $33.78 $238,457 - $338,306
-10,015 Reduced 49.86%
10,071 $314,000
Q3 2019

Jul 12, 2023
SELL
$21.57 - $31.37 $216,023 - $314,170
-10,015 Reduced 49.86%
10,071 $262,000
Q3 2019

Mar 22, 2023
SELL
$21.57 - $31.37 $67,298 - $97,874
-3,120 Reduced 23.65%
10,071 $262,000
Q3 2019

Nov 14, 2019
BUY
$21.57 - $31.37 $217,231 - $315,927
10,071 New
10,071 $262,000
Q2 2019

Jul 12, 2023
SELL
$19.51 - $28.31 $195,392 - $283,524
-10,015 Reduced 49.86%
10,071 $230 Million

Others Institutions Holding YMAB

# of Institutions
106
Shares Held
24.5M
Call Options Held
40.3K
Put Options Held
400
View Full List

About Y-mAbs Therapeutics, Inc.

YMAB Quotes by TradingView
  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email